Use of Size and a Copolymer Design Feature To Improve the Biodistribution and the Enhanced Permeability and Retention Effect of Doxorubicin-Loaded Mesoporous Silica Nanoparticles in a Murine Xenograft Tumor Model
Source abstract
Abstract
A key challenge for improving the efficacy of passive drug delivery to tumor sites by a nanocarrier is to limit reticuloendothelial system uptake and to maximize the enhanced permeability and retention effect. We demonstrate that size reduction and surface functionalization of mesoporous silica nanoparticles (MSNP) with a polyethyleneimine-polyethylene glycol copolymer reduces particle opsonization while enhancing the passive delivery of monodispersed, 50 nm doxorubicin-laden MSNP to a human squamous carcinoma xenograft in nude mice after intravenous injection. Using near-infrared fluorescence imaging and elemental Si analysis, we demonstrate passive accumulation of ∼12% of the tail vein-injected particle load at the tumor site, where there is effective cellular uptake and the delivery of doxorubicin to KB-31 cells. This was accompanied by the induction of apoptosis and an enhanced rate of tumor shrinking compared to free doxorubicin. The improved drug delivery was accompanied by a significant reduction in systemic side effects such as animal weight loss as well as reduced liver and renal injury. These results demonstrate that it is possible to achieve effective passive tumor targeting by MSNP size reduction as well as by introducing steric hindrance and electrostatic repulsion through coating with a copolymer. Further endowment of this multifunctional drug delivery platform with targeting ligands and nanovalves may further enhance cell-specific targeting and on-demand release.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Radiation Therapy and Dosimetry
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Division of NanoMedicine, Department of Medicine, University of California, Los Angeles, California, United States
Department of Chemistry & Biochemistry, University of California, Los Angeles, California, United States
California NanoSystems Institute, University of California, Los Angeles, California, United States
References (64)
Show source-provided references
1. Lu J. · Small · 2007 · 3 · 134110.1002/smll.200700005 ↗
2. He Q. · Small · 2011 · 7 · 27110.1002/smll.201001459 ↗
3. Lee C.-H. · Adv. Funct. Mater. · 2009 · 19 · 21510.1002/adfm.200800753 ↗
4. Liong M. · ACS Nano · 2008 · 2 · 88910.1021/nn800072t ↗
5. Meng H. · ACS Nano · 2010 · 4 · 453910.1021/nn100690m ↗
6. Meng H. · J. Am. Chem. Soc. · 2010 · 132 · 1269010.1021/ja104501a ↗
7. Xia T. · ACS Nano · 2009 · 3 · 327310.1021/nn900918w ↗
8. Radu D. R. · J. Am. Chem. Soc. · 2004 · 126 · 1321610.1021/ja046275m ↗
9. Slowing I. I. · J. Am. Chem. Soc. · 2007 · 129 · 884510.1021/ja0719780 ↗
10. Lee C.-H. · Angew. Chem., Int. Ed. · 2010 · 49 · 821410.1002/anie.201002639 ↗
11. Liu T. · Biomaterials · 2011 · 32 · 165710.1016/j.biomaterials.2010.10.035 ↗
12. Al Shamsi M. · Chem. Res. Toxicol. · 2010 · 23 · 179610.1021/tx100245j ↗
13. Lu J. · Small · 2010 · 6 · 179410.1002/smll.201000538 ↗
14. Davis M. E. · Nat. Rev. Drug Discovery · 2008 · 7 · 77110.1038/nrd2614 ↗
15. Nel A. E. · Nat. Mater. · 2009 · 8 · 54310.1038/nmat2442 ↗
16. Ruenraroengsak P. · J. Controlled Release · 2010 · 141 · 26510.1016/j.jconrel.2009.10.032 ↗
17. de Wolf H. K. · Int. J. Pharm. · 2007 · 331 · 16710.1016/j.ijpharm.2006.10.029 ↗
18. Nie S. · Annu. Rev. Biomed. Eng. · 2007 · 9 · 12.110.1146/annurev.bioeng.9.060906.151959 ↗
19. Perrault S. D. · Nano Lett. · 2009 · 9 · 190910.1021/nl900031y ↗
20. Ferrari M. · Nat. Rev. Cancer · 2005 · 5 · 16110.1038/nrc1566 ↗
21. Maeda H. · Eur. J. Pharm. Biopharm. · 2009 · 71 · 40910.1016/j.ejpb.2008.11.010 ↗
22. Torchilin V. · Adv. Drug Delivery Rev. · 2011 · 63 · 13110.1016/j.addr.2010.03.011 ↗
23. Iyer A. K. · Drug Discovery Today · 2006 · 11 · 81210.1016/j.drudis.2006.07.005 ↗
24. Lee H. · Mol. Pharmaceutics · 2010 · 7 · 119510.1021/mp100038h ↗
25. Cho K. · Clin. Cancer Res. · 2008 · 14 · 131010.1158/1078-0432.CCR-07-1441 ↗
26. Maeda H. · 2004 · 519 · 2910.1007/0-306-47932-X_2 ↗
27. Frangioni J. V. · Curr. Opin. Chem. Biol. · 2003 · 7 · 62610.1016/j.cbpa.2003.08.007 ↗
28. Farist F. · Clin. Phys. Phgsiol. Meas. · 1991 · 12 · 35310.1088/0143-0815/12/4/005 ↗
29. Bettio A. · J. Nucl. Med. · 2006 · 47 · 1153
30. Kaul G. · J. Drug Target · 2004 · 12 · 58510.1080/10611860400013451 ↗
31. Verbaan F. J. · J. Gene Med. · 2004 · 6 · 6410.1002/jgm.475 ↗
32. Fenske D. · Curr. Opin. Mol. Ther. · 2001 · 3 · 153
33. Gamen S. · Exp. Cell Res. · 2000 · 258 · 22310.1006/excr.2000.4924 ↗
34. Garg A. · J. Clin. Endocrinol. Metab. · 2002 · 87 · 301910.1210/jcem.87.7.8736 ↗
35. Nomura R. · Am. J. Roentgenol. · 2007 · 189 · 148410.2214/AJR.07.2809 ↗
36. Kandutsch S. · Eur. J. Surg. Oncol. · 2008 · 34 · 123110.1016/j.ejso.2008.01.001 ↗
37. Yagmurca M. · Clin. Chim. Acta · 2004 · 348 · 2710.1016/j.cccn.2004.03.035 ↗
38. Arola O. J. · Cancer Res. · 2000 · 60 · 1789
39. Slowing I. I. · Small · 2009 · 5 · 5710.1002/smll.200800926 ↗
40. Kursa M. · Bioconjugate Chem. · 2002 · 14 · 22210.1021/bc0256087 ↗
41. Kircheis R. · Cancer Gene. Ther. · 2002 · 9 · 67310.1038/sj.cgt.7700487 ↗
42. Febvay S. · Nano Lett. · 2010 · 10 · 221110.1021/nl101157z ↗
43. Petersen H. · Bioconjugate Chem. · 2002 · 13 · 84510.1021/bc025529v ↗
44. Tang G. P. · Biomaterials · 2003 · 24 · 235110.1016/S0142-9612(03)00029-2 ↗
45. Kunath K. · Pharm. Res. · 2002 · 19 · 81010.1023/A:1016152831963 ↗
46. Zhang S. · Biomaterials · 2010 · 31 · 95210.1016/j.biomaterials.2009.10.011 ↗
47. Kawano T. · J. Controlled Release · 2006 · 111 · 38210.1016/j.jconrel.2005.12.022 ↗
48. Thierry B. · Langmuir · 2008 · 24 · 814310.1021/la8007206 ↗
49. Fang J. · Adv. Drug Delivery Rev. · 2011 · 63 · 13610.1016/j.addr.2010.04.009 ↗
50. Suzuki M. · J. Natl. Cancer Inst. · 1981 · 67 · 663
51. Seki T. · Cancer Sci. · 2009 · 100 · 242610.1111/j.1349-7006.2009.01323.x ↗
52. Minko T. · Pharm. Res. · 2000 · 17 · 50510.1023/A:1007500412442 ↗
53. Sugahara K. N. · Science · 2010 · 328 · 103110.1126/science.1183057 ↗
54. Maeda H. · Bioconjugate Chem. · 2010 · 21 · 79710.1021/bc100070g ↗
55. Mao S. · Pharm. Res. · 2005 · 22 · 205810.1007/s11095-005-8175-y ↗
56. Zhang H. · ACS Nano · 2011
57. Portney N. · Anal. Bioanal. Chem. · 2006 · 384 · 62010.1007/s00216-005-0247-7 ↗
58. Vallet-Regi M. · Chem. Mater. · 2000 · 13 · 30810.1021/cm0011559 ↗
59. Hayek E. R. · N. Engl. J. Med. · 2005 · 352 · 245610.1056/NEJM200506093522321 ↗
60. Li S.-D. · Mol. Pharmaceutics · 2008 · 5 · 49610.1021/mp800049w ↗
61. Souris J. S. · Biomaterials · 2010 · 31 · 556410.1016/j.biomaterials.2010.03.048 ↗
62. Noguchi Y. · Cancer Sci. · 1998 · 89 · 307
63. Cauda V. · Microporous Mesoporous Mater. · 2010 · 132 · 6010.1016/j.micromeso.2009.11.015 ↗
64. Meng H. · ACS Nano · 2010 · 4 · 277310.1021/nn100448z ↗